With our AI-enabled drug discovery platform and the dedication of our brilliant, hard-working team, we have discovered differentiated therapies for some of the most challenging and pervasive diseases — at record pace.
We’re immensely proud of how far we’ve come since our founding in 2019. And we’re just getting started.
Mechanism: Novel (Non-Kinase)
Indication: Atopic Dermatitis
ENV-294 is a first-in-class, once-daily oral small molecule with a Dupi-like efficacy and safety profile, with pan-endotype potential in atopic dermatitis and other inflammatory conditions. We believe ENV-294 has pipeline-in-a-product potential. ENV-294 has completed Phase 1b trials and has initiated Phase 2a trials in atopic dermatitis.
Mechanism: Novel (Non-Kinase)
Indication: Asthma
Demonstrating its pipeline-in-a-product potential, ENV-294 has initiated Phase 2a trials in asthma.
Mechanism: Novel (Hormone Mimetic)
Indication: post-Weight Loss Maintenance
ENV-308 is a first-in-class, daily oral small molecule that sustains long-term metabolic health, including maintenance after initial weight loss. ENV-308 is currently in Phase 1 trials.
Mechanism: Novel (TL1A+ Pathway Inhibitor)
Indication: Inflammatory Bowel Disease
ENV-6946 is a first-in-class, gut-preferred, once-daily oral small molecule that offers a "multi-biologic in a pill" potential via a novel single target for the treatment of inflammatory bowel disease. ENV-6946 is currently in Phase 1 trials.
ENV-294 is a first-in-class, once-daily oral small molecule with a Dupi-like efficacy and safety profile, with pan-endotype potential in atopic dermatitis and other inflammatory conditions. We believe ENV-294 has pipeline-in-a-product potential. ENV-294 has completed Phase 1b trials and has initiated Phase 2a trials in atopic dermatitis.
Demonstrating its pipeline-in-a-product potential, ENV-294 has initiated Phase 2a trials in asthma.
ENV-308 is a first-in-class, daily oral small molecule that sustains long-term metabolic health, including maintenance after initial weight loss. ENV-308 is currently in Phase 1 trials.
ENV-6946 is a first-in-class, gut-preferred, once-daily oral small molecule that offers a "multi-biologic in a pill" potential via a novel single target for the treatment of inflammatory bowel disease. ENV-6946 is currently in Phase 1 trials.
Development Candidate Declared
THE PROBLEM
Over 10% (30M+) of the US population suffers from atopic dermatitis, commonly known as eczema. Yet, today’s treatments for moderate-to-severe eczema either rely on injectables that pose a significant barrier to patient care or oral therapies that come with potentially serious toxicities. Moreover, despite these treatments, half of all eczema to atopic dermatitis patients respond poorly to therapy.
THE MOLECULE
We are developing a first-in-class medicine that fights inflammation in a new way. This novel mechanism allows it to exert potentially powerful anti-inflammatory effects without the same toxicities that have burdened previous treatments – and can be delivered orally via a pill.
THE PROGRESS
Our molecule has demonstrated robust efficacy comparable to Jak-inhibitors in preclinical atopic dermatitis models but without their concomitant risks as evidenced by pre-clinical safety testing. It is currently in Phase 1b clinical trials.
THE PROBLEM
Metabolic health shapes how we live, age and feel everyday. Yet for hundreds of millions of people, it slips out of balance. Impaired metabolic health.leads to diabetes, weight gain, mental health disorders, cardiovascular disease, fatty liver disease, and reduced quality of life. Many people turn to a range of medications to try to regulate their weight, restore metabolic balance, and maintain long-term metabolic health, , but many of those therapies cannot be used over the long term or fail to work durably, whether because of tolerability, cost, access, or high discontinuation rates. When treatment stops, the majority of patients rapidly lose the benefits they achieved, leaving no effective solution for lasting maintenance.
THE MOLECULE
We are developing a first-in-class small-molecule medicine designed to support long-term metabolic balance. ENV-308 mimics an endogenous hormone that engages central satiety and reward pathways while restoring metabolic sensitivity for weight maintenance. This differentiated mechanism enables appetite regulation and metabolic control without relying on incretin signaling — and is designed for once-daily oral dosing suitable for chronic use, therefore replacing the need for long term injectables.
THE PROGRESS
ENV-308 has demonstrated sustained appetite suppression, complete prevention of weight regain following GLP-1 withdrawal, and steady weight maintenance in preclinical models at any target weight., The molecule has shown a favorable safety and tolerability profile in IND-enabling studies and is advancing through Phase 1 trials in overweight / obese and healthy individuals.
THE PROBLEM
Inflammatory bowel disease, or IBD, which includes both Crohn’s disease and Ulcerative Colitis, is a chronic autoimmune disorder that damages the digestive tract and disrupts the lives of more than 3 million people in the United States. IBD has limited treatment options that have proven to cause long-term remission in patients.
Moreover, many safe existing treatments have to be delivered as injections or pills that come with significant safety liabilities.
THE MOLECULE
We are developing a new therapeutic approach to treating IBD. Our first-in-class molecule hits multiple clinically validated pathways simultaneously, has been engineered to be preferentially present in the gut, and can be administered as a convenient pill. With ESN-6946, we have the potential to deliver improved safety, efficacy, and convenience.
THE PROGRESS
This powerful molecule is currently in Phase 1 trials.
Together, we can rapidly multiply humanity’s knowledge of the natural
world’s chemistry and solve many of the greatest challenges in human
and planetary health. We’d love your support.